SLIT3 and hepatocellular carcinoma: Based on the results from this study, we strongly believe that administration of recombinant Slit3 is a novel potential therapeutic approach for the treatment of HCC, however further investigations are necessary in order to elucidate its potency and efficacy in patients with HCC.